Aims The EMPA-REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin. Overexpression and Ca
2+
-handling in human and murine ventricular myocytes.
Methods and results
Myocytes from wild-type mice, mice with transverse aortic constriction (TAC) as a model of HF, and human failing ventricular myocytes were exposed to empagliflozin (1 μmol/L) or vehicle. CaMKII activity was assessed by CaMKII-histone deacetylase pulldown assay. Ca 2+ spark frequency (CaSpF) as a measure of sarcoplasmic reticulum (SR) Ca 2+ leak was investigated by confocal microscopy. [Na + ] i was measured using Na + /Ca 2+ -exchanger (NCX) currents (whole-cell patch clamp). Compared with vehicle, 24 h empagliflozin exposure of murine myocytes reduced CaMKII activity (1.6 ± 0.7 vs. 4.2 ± 0.9, P < 0.05, n = 10 mice), and also CaMKII-dependent ryanodine receptor phosphorylation (0.8 ± 0.1 vs. 1.0 ± 0.1, P < 0.05, n = 11 mice), with similar results upon TAC. In murine myocytes, empagliflozin reduced CaSpF (TAC: 1.7 ± 0.3 vs. 2.5 ± 0.4 1/100 μm À1 s À1 , P < 0.05, n = 4 mice) but increased SR Ca 2+ load and Ca 2+ transient amplitude. Importantly, empagliflozin also significantly reduced CaSpF in human failing ventricular myocytes (1 ± 0.2 vs. 3.3 ± 0.9, P < 0.05, n = 4 patients), while Ca 2+ transient amplitude was increased (F/F 0 : 0.53 ± 0.05 vs. 0.36 ± 0.02, P < 0.05, n = 3 patients). In contrast, 30 min exposure with empagliflozin did not affect CaMKII activity nor Ca 2+ 
Background
Treatment of diabetic patients with cardiovascular disease with the novel anti-diabetic drug empagliflozin, a selective inhibitor of sodium-dependent glucose transporter 2 (SGLT2) in the renal proximal tubules, reduced the incidence of cardiovascular death by 38% (EMPA-REG OUTCOME trial, n = 7020 patients). 1 The underlying mechanisms are hotly discussed. Surprisingly, the beneficial effects were not driven by a reduction in ischaemic endpoints (stroke or myocardial infarction) but by a reduction in the risk of hospitalization for heart failure (HF). 1 In addition, empagliflozin exerts the same beneficial cardiovascular effects after adjustment for ischaemic risk factors (blood pressure, low-density lipoprotein cholesterol, HbA1c). 2 In a mediation analysis of this trial, changes in haematocrit (and haemoglobin) but not HbA1c appeared to be the variables with the largest impact on the risk of cardiovascular death. 3 This argues strongly against glycaemic control as the underlying cardioprotective mechanism. 4 As a consequence, large Phase III trials are currently initiated that investigate empagliflozin in non-diabetic patients with HF (EMPEROR and EMPERIAL trial programs). Interestingly, in a non-diabetic mouse model of afterload-induced HF, empagliflozin prevented worsening of left ventricular function. 5 Overexpression and activation of Ca 2+ /calmodulin-dependent kinase II (CaMKII) are hallmarks of HF 3 and also found in diabetic patients, 4 leading to increased diastolic Ca 2+ leak from the sarcoplasmic reticulum (SR) and reduced SR Ca 2+ load, causing contractile dysfunction and arrhythmias. 3 Interestingly, CaMKII is activated by increased cytosolic Ca 2+ concentrations.
Aims
We tested whether empagliflozin inhibits CaMKII activity and diastolic SR Ca 2+ leak in cultured human and murine ventricular cardiomyocytes.
Methods
Experiments conform to the Declaration of Helsinki and were approved by local authorities. Left ventricular myocardium was acquired from explanted hearts of heart transplant recipients with end-stage HF (patient characteristics in Table S1 ). Atrial tissue was acquired from patients undergoing coronary artery bypass grafting. Written consent had been given prior to tissue donation. For some experiments, C57BL/6 mice (8-12 weeks) were used, and HF was induced by transverse aortic constriction (TAC; 5 weeks, as previously described 6 ). Echocardiographic data on heart structure and function of TAC mice are shown in Table  S2 . Isolated cardiomyocytes were exposed to either vehicle or 1 μmol/L empagliflozin. This concentration is in the range of the typical plasma concentration upon 25 mg q. d. oral treatment of patients. 7 CaMKII activity was measured by CaMKII-histone deacetylase (HDAC4) pulldown normalized to CaMKII expression. 8 Cell isolation, culture, Western blots, and measurement of Na + and Ca 2+ handling were employed as previously described.
9,10 Cardiomyocyte survival after 30 min or 24 h exposure to empagliflozin or vehicle control was not significantly different. Whole-cell voltage-clamp patch-clamp experiments were performed as described previously, and subsarcolemmal [Na + ] i was calculated using the Nernst equation.
11 Liquid chromatography-mass spectrometry (LC-MS) from SGLT2 gel bands from non-failing and failing human myocardium and high-resolution selected reaction monitoring (HR-SRM) for SGLT2 from human failing myocardium, and murine kidney and myocardium were performed as previously described. Data are shown as mean ± SEM; normality was tested using the Shapiro-Wilk normality test and parametric [ANOVA or (paired) Student's t-test] or non-parametric (Mann-Whitney test or Wilcoxon signed-rank test) tests were used as appropriate. An extended methods section can be found in the Supporting Information.
Results
CaMKII activity was measured using CaMKII pulldown by HDAC4 binding. Interestingly, 24 h exposure of murine wildtype (WT) ventricular cardiomyocytes to empagliflozin (1 μmol/L) significantly reduced CaMKII activity from 4.2 ± 0.9 to 1.6 ± 0.7 (P < 0.05, n = 10 mice, Figure 1A Figure 1C ). Accordingly, CaMKII-dependent phosphorylation of RyR2 (at serine 2814) was significantly decreased, while the protein kinase A (PKA)-dependent phosphorylation (at S2809) was unaltered upon 24 h exposure to empagliflozin ( Figure 1D) . Interestingly, phosphorylation of phospholamban (PLN) at threonine 17, perhaps the most frequently studied CaMKII phospho-site, was significantly reduced by 24 h empagliflozin exposure ( Figure 1E) .
In order to test if empagliflozin also affects CaMKIIdependent SR Ca 2+ leak in HF, ventricular myocytes were isolated from mice with HF upon TAC and from explanted hearts of patients with end-stage HF. Intriguingly, compared with vehicle, 24 h empagliflozin exposure significantly reduced CaSpF in TAC myocytes and human failing ventricular cardiomyocytes (Figure 2A ). This empagliflozin effect was not restricted to HF. Treatment with empagliflozin also reduced CaSpF in human atrial cardiomyocytes (Figure 2A) . Accordingly, 24 h empagliflozin exposure significantly reduced CaMKII activity (CaMKII pulldown by HDAC binding) and CaMKII-dependent RyR2 and PLN phosphorylation in Empagliflozin reduces CaMKII activity failing TAC cardiomyocytes ( Figure 2B ) and CaMKIIdependent RyR2 phosphorylation in human failing ventricular myocytes ( Figure 2C ). PKA-dependent RyR2 phosphorylation (at 2809), on the other hand, was not affected by empagliflozin in both in TAC and human failing cardiomyocytes ( Figure 2B and C) . Expression of neither RyR2 nor PLN was significantly altered.
Increased SR Ca
2+ load can lead to increased systolic SR Ca 2+ release and improved contractile function. We show here that, compared with vehicle, 24 h empagliflozin exposure significantly increased Ca 2+ transient amplitude (CaTransAmpl) in both healthy murine ventricular myocytes and failing ventricular myocytes from TAC mice and human failing hearts ( Figure 3A) . This increase was less pronounced Figure 3B ). Therefore, empagliflozin may rather directly impair Na + entry or elimination. To test if empagliflozin may inhibit SGLT2 in the heart, which is a Na + transporter, we analysed SGLT2 expression in ventricular myocardium from three patients with end-stage HF and three nonfailing donor hearts by LC-MS. No SGLT2 expression was detected using this methodology (data not shown). We further analysed SGLT2 expression by HR-SRM in murine WT myocardium and kidney, TAC myocardium, and human failing myocardium. In contrast to a robust SGLT2 expression in murine kidney, no SGLT2 signal was detected in myocardium ( Figure  3D ), full data set linked in the Supporting Information), which is in accordance with previous data. 13 Thus, cardiac SGLT2 inhibition can be excluded as potential mechanism of action of empagliflozin on the heart. Baartscheer Figure 3C ).
Conclusions
We show for the first time that empagliflozin potently reduces CaMKII activity in isolated failing and non-failing murine ventricular myocytes. More importantly, empagliflozin also reduced CaMKII-dependent phosphorylation of RyR2 in not only murine but also failing human ventricular myocytes. This results in a significantly reduced SR Ca 2+ leak and improved contractility as measured by significantly increased Ca 2+ transient amplitude in murine (TAC) and human failing ventricular myocytes. The mechanism by which empagliflozin reduces CaMKII activity has yet to be discerned, but our data demonstrate that empagliflozin may be useful in the treatment of pathologies with increased CaMKII activity, such as HF. 
Supporting information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Table S1 . Clinical characteristics of patient, from which atrial biopsies were obtained (upper table), or from which left ventricular tissue of explanted hearts (after heart transplantation, lower table) was used. y = yes, n = no, Nr = number, CAD = coronary artery disease, ICM = ischemic cardiomyopathy, DCM = dilated cardiomyopathy, EF = ejection fraction in %, LVEDD = left ventricular enddiastolic diameter in mm, m = male, SR = sinus rhythm, CABG = coronary artery bypass graft, valves = valvular dysfunction, MR = mitral regurgitation, TR = tricuspid regurgitation x°= indicated severity degree according to international standards, Art Hyp = arterial hypertension, KD = kidney disease, GFR = glomerular filtration rate in ml/min, NTproBNP in pg/ml (internal cutoff <150 pg/ml). Table S2 . Echocardiographic data obtained from 16 mice. OP = TAC surgery, bpm = beats per minute, LV = left ventricle, AWThd = anterior wall thickness in diastole, PWThd = posterior wall thickness in diastole, LVIDs = left ventricular internal diameter in systole, LVIDd = left ventricular internal diameter in diastole, *P < 0.05 versus respective pre-OP-measurement (Student's t-test).
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